Sm04554

[Hemo]

I'm not gonna harp on about the phase IIb delay anymore, but I just re-read their initial study's timeline which "involved a 90‐day once‐a‐day treatment period and a 45‐day post‐treatment follow up." (this was taken from their website). Extending their phase IIb by 45 days simply allows them to take the same 45 day post-treatment measure as the initial phase II, at least in my opinion (for a total 135 day trial, same as the first).

[20legend]

On clinical trails, the SM phase 2b trials isn't recruitment any more. Guess they got the required people.
It say it should finish by April so hopefully sometime next month we got a positive update from them.

In the meantime all we can do if find out about their molecule. Coz I think many ppl will be willing to give this a try.

[TooMuchHairWontKillYou]

Interesting article http://www.readcube.com/articles/10.1038%2Fnbt0216-120

But can't read the second page. If someone has access to it please copy it here

[baldybald]

We need to pay to see it though

[allTheGoodNamesAreTaken]

"“We have good evidence that bimatoprost [Latisse] stimulates hair growth, but skin absorption with our formulation was less than 1% so most of it was wasted,” he says. Allergan has since developed a new formulation with increased scalp penetrance, which will enter phase 1 safety testing in February."

I didn't know about this.

[stratowich]

Interesting article http://www.readcube.com/articles/10.1038%2Fnbt0216-120

But can't read the second page. If someone has access to it please copy it here

Nice to see a well written article on AGA in a high profile journal like Nature Biotechnology.

There isn't actually too much information on the second page (the article only consists of 2 pages). However, there is mentioning of another Milan-based company developing a topical DHT antagonist which sounds to have potentials:
"The oral DHT inhibitor Propecia, also used in a higher dose for treating enlarged prostates, slows hair loss but has potential side effects that include impotence and dizziness. Moreover, the drug is approved only for men, since exposures during pregnancy can harm the fetus.
Instead, Cassiopea of Milan, Italy is developing a topical DHT antagonist called Breezula for alopecia treatment. According to the company’s chief executive officer, Diana Harbort, the drug breaks down into harmless byproducts on entering circulation. If approved, Breezula would be the first anti-DHT compound available for use in both men and women. Currently a boutique firm specializing in dermatology, Cassiopeia was spun off by its parent company, Cosmo Pharmaceuticals, in January 2015."

[Hubris]

Interesting article http://www.readcube.com/articles/10.1038%2Fnbt0216-120

But can't read the second page. If someone has access to it please copy it here

Very interesting article. What I could read of it anyway.

[paleocapa89]

Nice to see a well written article on AGA in a high profile journal like Nature Biotechnology.

There isn't actually too much information on the second page (the article only consists of 2 pages). However, there is mentioning of another Milan-based company developing a topical DHT antagonist which sounds to have potentials:"[/I]

That's CB-03-01

[nameless]

Interesting article http://www.readcube.com/articles/10.1038%2Fnbt0216-120

But can't read the second page. If someone has access to it please copy it here

Wilma Bergfield says the results seem encouraging. That sounds kind of tame.

[Hemo]

Wilma Bergfield says the results seem encouraging. That sounds kind of tame.

The first paragraph also says they plan to move onto phase 3. You think they'd move on with "tame" results?